Oncopeptides AB (publ)
Stockholm Stock ExchangeTotal Valuation
Oncopeptides AB (publ) carries a market capitalization of 399.00M, placing it among publicly traded companies globally. Its enterprise value stands at 287.41M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 399.00M |
| Enterprise Value | 287.41M |
Share Statistics
Oncopeptides AB (publ) currently has 381.15M shares outstanding.
| Shares Outstanding | 381.15M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | 4.34 |
| PB Ratio | N/A |
| P/TBV Ratio | 4.71 |
| P/FCF Ratio | -1.87 |
| P/OCF Ratio | -1.87 |
Enterprise Valuation
| EV / Sales | 3.45 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Oncopeptides AB (publ) maintains a current ratio of 4.55, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.55 |
| Quick Ratio | 3.64 |
| Debt / Equity | 170.35 |
| Debt / EBITDA | -0.65 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -99.30 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.37 |
Taxes
| Income Tax | 1.49M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Oncopeptides AB (publ)'s stock has declined approximately -5.22989% over the past 52 weeks. The 50-day moving average sits at 1.62, while the 200-day moving average is 3.16.
| Beta (5Y) | N/A |
| 52-Week Price Change | -5.22989% |
| 50-Day Moving Average | 1.62 |
| 200-Day Moving Average | 3.16 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Oncopeptides AB (publ) generated 83.35M in revenue and converted that into -221.10M in net income, yielding earnings per share of -0.87. EBITDA reached -202.35M, while operating income came in at -202.35M.
| Revenue | 83.35M |
| Gross Profit | 80.49M |
| Operating Income | -202.35M |
| Pretax Income | -219.61M |
| Net Income | -221.10M |
| EBITDA | -202.35M |
| EBIT | -202.35M |
| Earnings Per Share (EPS) | -0.87 |
Balance Sheet
Oncopeptides AB (publ) holds 205.15M in cash and equivalents against 130.80M in total debt, resulting in a net debt position of -74.35M.
| Cash & Cash Equivalents | 205.15M |
| Total Debt | 130.80M |
| Net Debt | -74.35M |
| Equity (Book Value) | N/A |
| Book Value Per Share | N/A |
| Working Capital | 200.04M |
Cash Flow
Oncopeptides AB (publ) produced -193.77M in operating cash flow over the past twelve months.
| Operating Cash Flow | -193.77M |
| Capital Expenditures | N/A |
| Free Cash Flow | -193.77M |
| FCF Per Share | -0.76 |
Margins
Oncopeptides AB (publ) operates with a gross margin of 96.57, reflecting its pricing power and cost economics. The operating margin of -242.77 and net profit margin of -265.27 provide insight into operational efficiency.
| Gross Margin | 96.57 |
| Operating Margin | -242.77 |
| Pretax Margin | -263.48 |
| Profit Margin | -265.27 |
| EBITDA Margin | -242.77 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 12.71 |
| FCF Yield | -53.56 |
Stock Splits
Oncopeptides AB (publ)'s most recent stock split took place on April 16, 2024 with a 1000:1403 split ratio.
| Last Split Date | 4/16/2024 |
| Split Ratio | 1000:1403 |
Scores
Oncopeptides AB (publ) posts an Altman Z-Score of -0.15, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.15 |